• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ADNI 中的血浆 miRNA 组学：有助于发现高危个体的特征。

The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals.

机构信息

Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.

Bioinformatics Unit, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.

出版信息

Alzheimers Dement. 2024 Nov;20(11):7479-7494. doi: 10.1002/alz.14157. Epub 2024 Sep 18.

DOI:10.1002/alz.14157
PMID:39291752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11567822/
Abstract

INTRODUCTION

MicroRNAs are short non-coding RNAs that control proteostasis at the systems level and are emerging as potential prognostic and diagnostic biomarkers for Alzheimer's disease (AD).

METHODS

We performed small RNA sequencing on plasma samples from 847 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.

RESULTS

We identified microRNA signatures that correlate with AD diagnoses and help predict the conversion from mild cognitive impairment (MCI) to AD.

DISCUSSION

Our data demonstrate that plasma microRNA signatures can be used to not only diagnose MCI, but also, critically, predict the conversion from MCI to AD. Moreover, combined with neuropsychological testing, plasma microRNAome evaluation helps predict MCI to AD conversion. These findings are of considerable public interest because they provide a path toward reducing indiscriminate utilization of costly and invasive testing by defining the at-risk segment of the aging population.

HIGHLIGHTS

We provide the first analysis of the plasma microRNAome for the ADNI study. The levels of several microRNAs can be used as biomarkers for the prediction of conversion from MCI to AD. Adding the evaluation of plasma microRNA levels to neuropsychological testing in a clinical setting increases the accuracy of MCI to AD conversion prediction.

摘要

简介

微小 RNA 是一种短的非编码 RNA，可在系统水平上控制蛋白质平衡，并且作为阿尔茨海默病 (AD) 的潜在预后和诊断生物标志物而出现。

方法

我们对 847 名阿尔茨海默病神经影像学倡议 (ADNI) 参与者的血浆样本进行了小 RNA 测序。

结果

我们确定了与 AD 诊断相关的 microRNA 特征，并有助于预测从轻度认知障碍 (MCI) 到 AD 的转化。

讨论

我们的数据表明，血浆 microRNA 特征不仅可用于诊断 MCI，而且关键是可预测 MCI 向 AD 的转化。此外，结合神经心理学测试，对血浆 microRNA 组的评估有助于预测 MCI 向 AD 的转化。这些发现具有相当大的公众利益，因为它们提供了一条途径，可以通过定义老龄化人口中的高危人群，减少对昂贵和侵入性测试的盲目使用。

要点

我们对 ADNI 研究中的血浆 microRNAome 进行了首次分析。几种 microRNA 的水平可用作从 MCI 到 AD 转化预测的生物标志物。在临床环境中，将血浆 microRNA 水平的评估添加到神经心理学测试中，可提高 MCI 向 AD 转化预测的准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/997f775ec366/ALZ-20-7479-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/afdda6e772ac/ALZ-20-7479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/6f4d373ae344/ALZ-20-7479-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/2f63fa235212/ALZ-20-7479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/ba1961b5b261/ALZ-20-7479-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/4baaff482bba/ALZ-20-7479-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/0cd9a1e69b63/ALZ-20-7479-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/bd3ed9e6da6a/ALZ-20-7479-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/997f775ec366/ALZ-20-7479-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/afdda6e772ac/ALZ-20-7479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/6f4d373ae344/ALZ-20-7479-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/2f63fa235212/ALZ-20-7479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/ba1961b5b261/ALZ-20-7479-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/4baaff482bba/ALZ-20-7479-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/0cd9a1e69b63/ALZ-20-7479-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/bd3ed9e6da6a/ALZ-20-7479-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b646/11567822/997f775ec366/ALZ-20-7479-g003.jpg

相似文献

1
The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals.ADNI 中的血浆 miRNA 组学：有助于发现高危个体的特征。
Alzheimers Dement. 2024 Nov;20(11):7479-7494. doi: 10.1002/alz.14157. Epub 2024 Sep 18.
2
Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.基于血浆生物标志物预测轻度认知障碍患者的纵向认知下降和阿尔茨海默病转化。
Cells. 2024 Jun 22;13(13):1085. doi: 10.3390/cells13131085.
3
Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.血清钙水平降低可能与轻度认知障碍向早期阿尔茨海默病转化有关：日本阿尔茨海默病神经影像学倡议研究。
J Alzheimers Dis. 2019;68(2):777-788. doi: 10.3233/JAD-181115.
4
Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.阿尔茨海默病神经影像学倡议 (ADNI) 血浆蛋白质组学数据集中，临床前阿尔茨海默病的多变量蛋白质标志物。
PLoS One. 2012;7(4):e34341. doi: 10.1371/journal.pone.0034341. Epub 2012 Apr 2.
5
Baseline serum glutamate: Implications for diagnosis and prediction in mild cognitive impairment and Alzheimer's disease of the Alzheimer's Disease Neuroimaging Initiative.基础血清谷氨酸：对阿尔茨海默病神经影像学倡议中轻度认知障碍和阿尔茨海默病的诊断和预测的影响。
J Clin Neurosci. 2024 Nov;129:110828. doi: 10.1016/j.jocn.2024.110828. Epub 2024 Sep 11.
6
Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.轻度认知障碍的神经心理学标准提高了诊断准确性、生物标志物关联性和进展率。
J Alzheimers Dis. 2014;42(1):275-89. doi: 10.3233/JAD-140276.
7
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.载脂蛋白E4对轻度认知障碍和阿尔茨海默病自动诊断分类器的影响。
Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.
8
Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对轻度认知障碍向阿尔茨海默病转化的预测价值增加。
Transl Neurodegener. 2020 Aug 3;9(1):30. doi: 10.1186/s40035-020-00210-5.
9
Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.血浆淀粉样蛋白和tau 在正常衰老、轻度认知障碍和阿尔茨海默病纵向研究中的变化。
Dement Geriatr Cogn Disord. 2019;48(3-4):180-195. doi: 10.1159/000505435. Epub 2020 Jan 28.
10
A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum.基于机器学习的阿尔茨海默病谱患者临床病程预测的整体方法。
J Alzheimers Dis. 2022;85(4):1639-1655. doi: 10.3233/JAD-210573.

引用本文的文献

1
Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.用于阿尔茨海默病早期诊断的循环生物标志物
Int J Mol Sci. 2025 Jul 27;26(15):7268. doi: 10.3390/ijms26157268.
2
Role of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure.代偿性miRNA网络在心力衰竭认知恢复中的作用
Noncoding RNA. 2025 Jun 12;11(3):45. doi: 10.3390/ncrna11030045.
3
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.临床前阿尔茨海默病在一个多民族队列中显示出循环神经元衍生细胞外囊泡微小RNA的改变。

本文引用的文献

1
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.基于生物标志物的阿尔茨海默病分期：原理与临床应用。
Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1.
2
Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers.人血浆微小RNA的纵向稳定性分析及其对疾病生物标志物的意义。
Sci Rep. 2024 Jan 25;14(1):2148. doi: 10.1038/s41598-024-52681-5.
3
Integrative Analysis of the Age-Related Dysregulated Genes Reveals an Inflammation and Immunity-Associated Regulatory Network in Alzheimer's Disease.
Alzheimers Dement. 2025 Mar;21(3):e70050. doi: 10.1002/alz.70050.
4
Circulating small RNAs shed new light on dementia risk.循环小RNA为痴呆风险带来新线索。
Alzheimers Dement. 2025 Feb;21(2):e14546. doi: 10.1002/alz.14546. Epub 2025 Jan 27.
5
Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives.用于阿尔茨海默病的第二代抗淀粉样蛋白单克隆抗体：现状与未来展望
Transl Neurodegener. 2025 Jan 27;14(1):6. doi: 10.1186/s40035-025-00465-w.
6
Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers.阿尔茨海默病连续体中的血浆 miRNA：与中枢生物标志物的关系。
Alzheimers Dement. 2024 Nov;20(11):7698-7714. doi: 10.1002/alz.14230. Epub 2024 Sep 18.
整合分析与年龄相关的失调基因揭示阿尔茨海默病中炎症和免疫相关的调控网络。
Mol Neurobiol. 2024 Aug;61(8):5353-5368. doi: 10.1007/s12035-023-03900-z. Epub 2024 Jan 8.
4
Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study.最佳血液 tau 标志物用于检测阿尔茨海默病神经病理学：免疫沉淀质谱法和尸检研究。
Acta Neuropathol. 2023 Dec 30;147(1):5. doi: 10.1007/s00401-023-02660-3.
5
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.阿尔茨海默病神经影像学倡议在阿尔茨海默病治疗时代：对 2021 年至 2022 年 ADNI 研究的回顾。
Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12.
6
Oxidative Stress Occurs Prior to Amyloid Aβ Plaque Formation and Tau Phosphorylation in Alzheimer's Disease: Role of Glutathione and Metal Ions.氧化应激发生在阿尔茨海默病的淀粉样 Aβ 斑块形成和 Tau 磷酸化之前：谷胱甘肽和金属离子的作用。
ACS Chem Neurosci. 2023 Sep 6;14(17):2944-2954. doi: 10.1021/acschemneuro.3c00486. Epub 2023 Aug 10.
7
Serum microRNAs associated with concussion in football players.与足球运动员脑震荡相关的血清微小核糖核酸
Front Neurol. 2023 Apr 18;14:1155479. doi: 10.3389/fneur.2023.1155479. eCollection 2023.
8
MiR-574-5P, miR-1827, and miR-4429 as Potential Biomarkers for Schizophrenia.miR-574-5P、miR-1827 和 miR-4429 作为精神分裂症的潜在生物标志物。
J Mol Neurosci. 2022 Feb;72(2):226-238. doi: 10.1007/s12031-021-01945-0. Epub 2021 Nov 22.
9
Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease.利用血液中的微小RNA预测阿尔茨海默病患者脑脊液中的P- tau/Aβ42水平
BMC Med. 2021 Nov 15;19(1):264. doi: 10.1186/s12916-021-02142-x.
10
The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives.基于 microRNA 的疗法在阿尔茨海默病中的应用前景：挑战与展望。
Mol Neurodegener. 2021 Nov 6;16(1):76. doi: 10.1186/s13024-021-00496-7.